Literature DB >> 14979443

Field efficacy of moxidectin 1 per cent against Thelazia callipaeda in naturally infected dogs.

R P Lia1, D Traversa, A Agostini, D Otranto.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14979443     DOI: 10.1136/vr.154.5.143

Source DB:  PubMed          Journal:  Vet Rec        ISSN: 0042-4900            Impact factor:   2.695


× No keyword cloud information.
  5 in total

1.  Diagnostic Ophthalmology.

Authors:  Marina L Leis; Lynne S Sandmeyer
Journal:  Can Vet J       Date:  2018-11       Impact factor: 1.008

2.  Therapeutic efficacy of milbemycin oxime/praziquantel oral formulation (Milbemax®) against Thelazia callipaeda in naturally infested dogs and cats.

Authors:  Bruna Motta; Manuela Schnyder; Fabrizio Solari Basano; Fabio Nägeli; Catherine Nägeli; Brigitte Schiessl; Egidio Mallia; Riccardo P Lia; Filipe Dantas-Torres; Domenico Otranto
Journal:  Parasit Vectors       Date:  2012-05-19       Impact factor: 3.876

Review 3.  Vector-borne nematode diseases in pets and humans in the Mediterranean Basin: An update.

Authors:  Djamel Tahir; Bernard Davoust; Philippe Parola
Journal:  Vet World       Date:  2019-10-26

4.  Efficacy of a formulation of sarolaner/moxidectin/pyrantel (Simparica Trio®) for the prevention of Thelazia callipaeda canine eyeworm infection.

Authors:  Marcos Antonio Bezerra-Santos; Jairo Alfonso Mendoza-Roldan; Giovanni Sgroi; Riccardo Paolo Lia; Giulia Venegoni; Fabrizio Solari Basano; Roose Nele; Sean P Mahabir; Stasia Borowski; Thomas Geurden; Domenico Otranto
Journal:  Parasit Vectors       Date:  2022-10-16       Impact factor: 4.047

Review 5.  Vector-borne helminths of dogs and humans in Europe.

Authors:  Domenico Otranto; Filipe Dantas-Torres; Emanuele Brianti; Donato Traversa; Dusan Petrić; Claudio Genchi; Gioia Capelli
Journal:  Parasit Vectors       Date:  2013-01-16       Impact factor: 3.876

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.